Description
Release form
Lyophilisate for solution for injection.
Packaging
5 ampoules complete with solvent.
Pharmacological action of
Cocarboxylase catalyzes the oxidative decarboxylation of alpha-keto acids (pyruvic, alpha-ketoglutaric, etc.).
Contraindications
Hypersensitivity.
Special instructions
Due to the presence of glycocholic acid as an adjuvant, with repeated and prolonged administration of the drug in patients with jaundice or severe cholestasis (changes in laboratory functional tests of the liver), liver function must be carefully monitored.
Deficiency of one or more vitamins should be corrected by administering a missing vitamin preparation.
Zernovit does not contain vitamin K, which can be administered separately if necessary.
After dilution, the drug is stable at a temperature not exceeding 25 ° C for 24 hours, but it is recommended that the drug be used immediately after dilution or stored for no more than 24 hours at a temperature of 2 ° to 8 ° C.
Influence on the ability to drive vehicles and operate machinery
Since Zernevit is intended for patients receiving parenteral nutrition and are in a moderate to severe condition, their ability to drive and operate machinery has not been evaluated.
Composition of
1 ampoule with powder for preparation of injection contains 50 mg cocarboxylase hydrochloride.
Dosage and administration
Cocarboxylase is administered s / c, v / m. The dose is set individually, depending on the nature of the disease and the severity of the patient’s condition. Adults: 50-100 mg / day, once, if necessary (diabetic coma) – again after 1-2 hours later they switch to a maintenance dose of 50 mg / day for circulatory failure 50 mg is administered 2 hours before the use of digitalis preparations 2-3 times a day. Children per day (in 1-2 doses): up to 3 months – 25 mg, from 4 months to 7 years – 25-50 mg, from 8 to 18 years old – 50-100 mg.
Side effects
Allergic reactions.
Drug interactions
Due to the presence of pyridoxine (vitamin B6) in the preparation, combined use with levodopa preparations is contraindicated due to the accelerated metabolism of levodopa with the participation of a pyridoxine-dependent enzyme. To prevent this interaction, a dopa-decarboxylase inhibitor, carbidopa, can be used.
Due to the presence of folic acid in the preparation, caution should be exercised when combined with antiepileptic drugs containing phenobarbital, phenytoin or primidone. Clinical observation and, if possible, monitoring of the content of antiepileptic drugs in the blood plasma, correction of the dosage regimen of the antiepileptic drug during and after stopping the use of folic acid is necessary.
Compatibility should be checked when preparing with other infusion solutions, especially if Zernevit is added to binary parenteral mixtures containing glucose, electrolytes and amino acid solutions, or to mixtures containing glucose, electrolytes, amino acid solutions and lipids.
The patient must inform the doctor of any medications that have been used previously.
Overdose
Overdose is mainly due to excessive doses of vitamin A.
Symptoms: in case of acute overdose of vitamin A (doses exceeding 150,000 ME) – gastrointestinal upsets, headache, increased intracranial pressure, edema of the optic nerve head, mental disorders, excitability, sometimes convulsions, delayed generalized desquamation of the epithelium in case of chronic overdose of vitamin A – increased intracranial pressure, cortical hyperostosis and premature fusion of the epiphyseal plate, which is usually expressed in the occurrence of sensitive or painful subcutaneous edema on the lower fingers limbs. An X-ray examination on the ulnar, fibula, clavicle and costal bones shows diaphyseal periosteal thickenings.
Treatment: discontinue use of the drug, reduce the use of calcium, increase diuresis and conduct adequate rehydration of the body.
Storage Conditions
In a dark place at a temperature not exceeding 20 ° C.
pharmacy terms of prescription
Form of Treatment
simply entails dlya inaektsiy and infusing
Indications
Hronycheskaya circulatory failure, heart disease Yshemycheskaya, angina, Prevention of acute ynfarkta myocardial
Deco Company, Russia
